A combined treatment for advanced oral XXXX .

@entity1 @entity14954 @entity5 @entity229 @entity957 @entity7468 @entity532 @entity17790 @entity1891 @entity1732 @entity1499 @entity34
Effects of preoperative chemotherapy with three courses of a combination of @entity1732 , @entity1891 , @entity14954 , @entity229 , and @entity1499 , with a leucovorin rescue, followed by surgery were studied in 43 @entity1 with @entity957 of the oral region. Before chemotherapy 34 @entity1 (79%) had @entity5 whereas nine @entity1 had @entity34 . The clinical response was very encouraging: 20 @entity1 (46%) achieved a clinical complete response and 23 @entity1 (54%) were judged as partial responders. Side effects of this chemotherapy were minimal and reversible. Between 15 and 22 days after the last course of chemotherapy @entity1 went to surgery. @entity532 did not occur. The surgical specimens were tested microscopically. The microphotographs showed small @entity5 rests with @entity7468 bordered by @entity17790 and separated from the healthy tissues. With a median follow-up of 36 months (range, 21-58 months) 74% of @entity1 are alive and 70% remain disease-free. Eleven @entity1 died but only five (11%) because of the failure of therapy. This combined therapy appears both safe and promising treatment for advanced @entity957 of the oral cavity. A further follow-up study needed to confirm the promising 5-year results.
